HRAIN BIOTECHNOLOGY
To explore the secrects of life and safeguard the human health
To explore the secrects of life and safeguard the human health
HRAIN BIOTECHNOLOGY ANALYSIS
Hrain Biotechnology is a biotechnology startup with the mission of exploring the secrets of life and safeguarding human health. Established in 2015, the company has garnered support from an authoritative scientific advisory committee and has formed key partnerships with internationally renowned universities and domestic research institutes. Partner institutions include the University of Southern California, Duke University, University of California, Los Angeles, Cell and Gene Therapy Center of Academy of Military Medical Sciences, and the Cancer Diagnosis and Treatment Institute of Xinqiao Hospital.
Notable for its recent CNY200.00M Series B investment on 30 September 2019, Hrain Biotechnology has attracted capital from Shenzhen Capital Group, ChiNext Qianhai Capital, and Junchenda Capital.
The company's commitment to pioneering biotechnological advancements, in conjunction with its strong financial backing, positions Hrain Biotechnology as an exciting investment opportunity within the realms of biotechnology and healthcare.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | Unknown | 2 |
|
26 Apr 2021 |
| Series B | CNY200.00M | 6 |
|
09 Sep 2020 |
| Series B | CNY200.00M | 2 |
|
30 Sep 2019 |
No recent news or press coverage available for HRAIN BIOTECHNOLOGY.
--logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
